Oncology Round-Up

First, the sobering but not unexpected news that effect sizes in trials of cancer immunotherapy drugs are on average 17% greater for progression-free survival (PFS) than for overall survival (OS).

An analysis of 51 trials reported in the Journal of Clinical Oncology revealed almost half showed a statistically significant benefit for progression-free survival, but no such benefit for overall survival. Obinutuzumab, bevacizumab and rituximab were